STOCKS TELEGRAPH

Author: Wasim Omar

  • DXF pre-market Climb – In for a Ride or False Optimism

    DXF pre-market Climb – In for a Ride or False Optimism

    Market participants looking towards Dunxin Financial Holdings Limited (DXF) woke up to big movements this morning. This was because, later in the after-hours of yesterday’s trade, and early in today’s premarket, traders saw a growth swing that was nothing short of extraordinary. Total gain as of yet, since yesterday’s trade initiated, has been close to 22.86% within a single day.

    DXF and Digital Copyrights Initiative

    The Chinese microfinance firm has been active in the prior months, frequently making rounds across news reports and digital chatter. In January, Dunxin announced a core partnership with an authorized digital copyrights institution, pointing to the company’s forward-looking strategic prospects. For instance, the partnership entails the establishment of a digital copyrights trade platform, along with the launch of derivative products.  This initiative is a crucial stepping-stone towards digitization and capitalization, which is still a fledgling concept in Chinese markets. Furthermore, the move is critical as a launching pad for expansion, pushing Dunxin towards market internationalization.

    Dunxin Aiming to Capture Metaverse Gains

    Earlier in the year, Dunxin Holdings has further stepped forward in the emerging metaverse industry, laying the foundation in crucial domains. These were inclusive of a computing power investment fund, along with an intelligence computing power center. These strategic initiatives are a testament to the company’s innovative vision and foresight, working to the benefit of company shareholders. This broader AI-based program has management and investors alike, largely optimistic, which offers a range of benefits. These include robust and real-time computing capabilities, a fundamental prerequisite for metaverse systems. Through the company’s innovative approach, it hopes to achieve these milestones through the integration of blockchain and cloud-based systems.

    External Drivers

    Broader factors could potentially be at play, which explains the sentiment surrounding the DXF  stock. The Ukraine-Russia crisis and its subsequent economic sanctions do not directly impact the Chinese microfinance industry. As a result, this market hype may potentially be coming at a time when investors are looking for safer bets through diversification. Moreover, projections of lowered Yuan loans in China and a slowing economy minimize credit risk exposure for Chinese microfinance firms.

    Conclusion

    At present, it is unclear whether the current DXF swing is related to the aforementioned company updates. What is clear is that stock is being bought heavily in the aftermarket and premarket, driving up the price in its wake. Chatter across social media suggests a short squeeze is underway, with the penny stock being caught up in wider market hype.

  • Growth Potential for ANPC, Despite Persistent Downward Spiral?

    Growth Potential for ANPC, Despite Persistent Downward Spiral?

    AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) is one penny stock that has traders’ attention gripped after yesterday’s trade session. Pushing into the pre-market, traders saw a net rise of 14.8%, reaching a peak of $0.75 at a certain point. This comes amidst a general bearish movement persisting from a month ago, losing 26.5% in value throughout this timeframe. In fact, this downward slide has persisted throughout the last twelve months and beyond. As of yet, ANPC stock stands at a mere 8.4% of the value it held at this date in 2021. The broader trajectory of the ANPC stock is laden with brief peaks in its general downward movement. These temporary yet frequent growth spurts are hardly sustained, and thus shortly undergo downward swings.

    Nature of the Biotech Industry

    The Chinese bio-medical firm is no anomaly to the biotech sector, where risk is initially high during initial phases. The absence of profitability during this frame of pharmaceuticals further points towards this progression. It further suggests the persistent bearish movement since 2020, may not be a potential red flag.

    AnPac Global Leader in Multicancer detection and Screening

    In fact, those familiar with the biotechnology realm are aware of the potential and promise AnPac likely holds. For instance, Frost & Sullivan ranked the firm as a global number one in the realm of multi-cancer detection and screening. The multinational US-based research firm arrived at this conclusion based on a number of parameters. Furthermore, AnPac, which holds a number of promising patents dating back to 2014, has achieved significant leaps in cancer treatment. Through its innovative technologies developed, AnPac is capable of detecting up to 16 different types of cancers. Moreover, its publishing of 4 technical papers for ASCO further highlights its commitment towards its vision towards cancer treatment.

    Independent Valuation Points to ANPC’s Undervaluation

    Another significant update that could potentially explain the sudden rise against bearish movement relates to a recent appraisal conducted. AnPac’s fully owned subsidiary, Changwei System Technology Co., Ltd had undergone an independent valuation last week. The value of the company was deemed as being approximately $90 million, suggesting its share price was heavily undervalued. The appraisal was invited after the board’s decision for the subsidiary to explore alternative strategic avenues, aimed at maximizing shareholder value. The firm’s integrated circuit chips, if properly implemented could bring a breakthrough within the medical domain.

    Conclusion

    AnPac stock has been on a persistent downward trajectory, given the nature of the biotechnological industry. However, experts in the domain point towards the innovative capabilities and potential of the company. The recent independent valuation of its fully owned subsidiary, Changwei System points to a significant undervaluation. This opens the door for alternative strategic avenues and potential shareholder value maximization.

  • CPNG Going in for the Kill – Tumultuous Trajectory amidst Robust Potential

    CPNG Going in for the Kill – Tumultuous Trajectory amidst Robust Potential

    Stock for Coupang, Inc. (CPNG) has been on a tumultuous roll today seeing a steady bullish climb of 10.5%. A sharp plummet of 7.3% then followed in the after-hours of trade. In fact, most of the last week had been sporadic for CPNG, both rising and dropping at substantial levels. The market continues to closely assess the ongoing trajectory, and what position to take with the stock.

    Classification Shifts for CPNG and Billionaire Investors

    Coupang Inc, the South Korean ecommerce giant holds immense growth potential, owing to a number of broader variables. A classification shift notified yesterday by a Swiss multinational investment bank, UBS, further indicated this. The bank had upgraded its classification of the CPNG stock from neutral to buy, formalizing market projections and optimism. Moreover, American investing giant Stanley Druckenmiller bet a whopping 20% of his worth on the company’s prospects. Similarly, Bill Ackman was amongst the early investors in the company, who partook in the IPO.

    These developments do not come in isolation, and factor in crucial economic and company-specific updates.

    E-Commerce in South Korea – An Industry with Immense Promise

    The country’s ecommerce sector is to further realize a potential CAGR of 19.92% for the period up till 2025. These findings, coming from credible market research, point to bifurcation in terms of varying product sectors, promising further opportunity. Given demographic factors surrounding Korea, the fashion industry along with food and beverages promises to drive forward online marketplaces. Moreover, skyrocketing rates of disposable income continue to enhance prospects for CPNG’s consumer-driven business model.

    CPNG Poised to Overtake Amazon

    Coupang Inc, holding the advantage of having overcome the industry’s barriers to entry is poised to significantly capture this gain. Its access to financing and its scale of operation have it dubbed as being the ‘Amazon of South Korea’. However, billionaire investors such as Druckenmiller and Ackman perceive Coupang to be far more lucrative than Amazon, for many reasons. For one, its growth potential, in a high-growth economy like South Korea, with rapid urbanization, gives it a clear edge. Secondly, its strategic diversification and integration with varying sectors significantly diminish its risk exposure. Thirdly, with the world shifting to a post-Covid context, the convenience brought on by e-commerce is likely to sky-rocket.

    Conclusion

    CPNG stock seems like an ideal option for a safe, long-term investment. The current dip in price, although concerning for retail investors, comes against the backdrop of strong market confidence. Investors continue to monitor movement for the stock, which is anticipated to ride along with a strong bullish trend, moving forward.

     

  • DNN in the Uranium Growth Boat. Industry Potential under the Spotlight

    DNN in the Uranium Growth Boat. Industry Potential under the Spotlight

    The small-cap Uranium player, Denison Mines Corp. (DNN) is a stock whose movements are worth keeping track of. Having risen by 6.79% during the day’s regular trade session, the after-hours saw a further climb of 6.94%. This bullish trend is a continuation of the momentum from t the prior month, appreciating by 34.11%

    Uranium Industry’s Recent Potential for Denison Mines

    DNN stock is part of a broader swing that the Uranium industry is currently undergoing, owing to market-related developments since February. Last year, investors perceived heightened potential for the industry, after interest from France in small modular nuclear reactors for energy purposes. Other European countries supported this motion in the broader discourse surrounding clean energy in the EU. The EU bloc, in November, had argued for a green classification to apply to nuclear power. Such a move, if successful would qualify Uranium for crucial subsidies. However, a number of EU states responded to the motion with strong resistance, deeming the mode unsafe and costly.

    Russia-Ukraine Crisis & Uranium Impacts

    The stalemate pertaining to the Uranium market in Europe came to an abrupt shift in February last month. Tensions along with the subsequent conflict between Ukraine and Russia brought a significant turn of events for the industry. Energy reliability for the world had come under the spotlight, and Uranium’s potential had further been at the center of discourse. German energy minister recently suggested a potential extension to its nuclear reactors, against the earlier implemented phase-out plan.

    DNN Fundamentals and Prospects

    DNN stock finds itself amongst this geopolitical hype, and its trade volume suggests the level of interest attracted. Given Denison Mines’ fundamentals, the company may be well suited to capture in on the anticipated gains for the industry. The company’s publishing of its annual reports on Friday has been a major driver in the market interest being observed. The year 2021 brought robust operational and financial results for Denison Mines, further enhancing investor confidence.

    The annual report further detailed a wide range of successful exploration programs initiated for the year 2022. Moreover, the company’s successful testing of ISR field tests in Phoenix is crucial for future growth potentials. This comes in an addition to a $41.4 million increase in physical uranium holdings. Collectively, these factors ensure Denison Mines’s economic feasibility and financial sustainability.

    Conclusion

    Denison Mines’ remarkable growth trend comes at an intersection between broader industry potential, and the company’s robust fundamentals. Uranium as a clean and reliable energy source has come under the public spotlight, resulting in a market frenzy. The company’s recent annual report enhances the overall confidence investors hold towards DNN.

  • Sudden Swing for PT Stock – Market Frenzy or Broader Factors at Play?

    Sudden Swing for PT Stock – Market Frenzy or Broader Factors at Play?

    After an impressive 13.64% climb, stock for Pintec Technology Holdings Limited (NASDAQ: PT) saw a tremendous shoot up in price. Into the after-hours of trade in the market, volume pushed price up by a stunning 44.14% rise, with no dip.

    No Stranger to Growth Spurts

    Stock for Pintec Technology is not new to these growth spurts, having experienced a similar swing earlier in January. Stock for the China-based consumer finance company saw a ballooning of over 183% during the aforementioned time frame. Its growth during the time was linked to the firm’s announcement of its annual financial reports and disclosures. The growth factors showcased instilled the company’s investors with confidence in relation to its sustainability and prospects.

    No current announcements by the company or verified reports, as of yet, conclusively identify factors driving up the current growth. PT stock, which is classed as a penny stock may well be caught up in a meme frenzy, based on the chatter observed across social media. Given the initial hype around the stock, retail traders are rushing in to gain exposure to this swiftly rising price. However, broader macroeconomic conditions may potentially explain this sustained growth, rather than a sporadic trajectory.

    Chinese Economic Slowdown

    A Reuters report earlier yesterday pointed to a steep decline in new Yuan loans following a peak from last month. Economists link this retreat to a slowing economy, which in turn reduces the banking and finance sectors’ burdens of a robust credit supply. For lending companies such as Pintec Technology, this suggests a reduction in liquidity requirement, as well as a substantial decrease in credit risk exposure. Reduced loan levels across the market further bring down operational costs to more manageable levels and allow efficient usage of acquired technologies. Variables such as these bring about positive future-looking projections for PT stock.

    CEO Victor Li

    Pintec Technology is ripe to capture gains by this macroeconomic push, given its strategic vision, and recent growth-related developments. CEO Victor Li, the winner of The Asian Banker Innovation Leadership Achievement Awards (2021), is a cornerstone of this vision. His vision is likely to drive the company in achieving sustainable expansion in the near future. Li is also responsible for a number of overseas market breakthroughs, such as in Australia and North America.

    Conclusion

    PT stock is currently witnessing swift growth, by ballooning upwards of 44% in a few hours. Social-media generated hype, along with a significant influence of broader factors, could explain the frenzy behind the stock. Macroeconomic conditions project the company to achieve operational efficiencies. Furthermore, CEO Victor Li’s leadership and credentials further boost investor confidence.

  • IMPP Stock on a Growth Rocket

    Share prices for Imperial Petroleum Inc (NASDAQ: IMPP) continue the extraordinary bullish momentum reported later last week. In just over two weeks, the stock has ballooned by upwards of 5.8 times its initial price. Currently standing at 3.98 in the after-hours of trade, the stock continues to impress the market, showing a growth spurt that is beyond ordinary circumstances. With US crude oil momentarily topping $130 a barrel, uncertainty regarding oil futures continued influencing trade in the stock market.

    Oil Prices Reach Historic Highs

    Previously, during the financial crunch of July 2008, global markets witnessed a similar peak in oil prices. Oil prices returning to these heights are alarming for the global economy, threatening to exacerbate inflationary pressures. Given recent developments, it is evident that as geopolitical tensions continue to broil, IMPP stockholders are the real winners.

    Given the magnitude of chatter surrounding it, market onlookers described IMPP as a meme stock earlier last year. This frenzy, however, is linked to more systematic economical shifts influenced by global geopolitics and oil supply. Investors are rushing to get their hands on oil futures, in the wake of the oil crisis reaching peaks not seen in over 14 years.

    IMPP well-positioned for Opportunity Capture

    The IMPP stock, in particular, has seen a substantial premium above competitors, and other players in the energy sectors. The ensuing crisis significantly enhances the potential of opportunity capture for Imperial Petroleum, which operates a cargo fleet for petroleum products. Furthermore, its plans for fleet expansion position the company for substantial growth. This growth is clearly substantiated, given the demand for heightened fuel, along with that of its shipment across the globe. This anticipation in demand and potentially increasing capacity is what enhances overall financial feasibility for the IMPP stock. The sheer trade volume of the stock, alongside its shooting share price, indicates the market’s quick response to these collective shifts. Traders continue to watch the IMPP stock closely if its price maintains within the bracket of $3.00 – $3.50. In doing so, positive growth momentum will likely persist.

    Conclusion

    Throughout the day, IMPP stock has seen remarkable growth, given a historic rise in crude oil prices. This momentum continued well into the after-hours of trade, indicating the frenzy surrounding it. Investors are betting on the shipping company in the wake of its increased capacity, and the sheer demand anticipated shortly.

  • WEAT ETF Skyrockets, Inverse to European Stocks Meltdown

    WEAT ETF Skyrockets, Inverse to European Stocks Meltdown

    The performance of Teucrium Wheat (NYSE: WEAT) has continued to impress keen stock traders, earlier on Friday. The premarket saw a continuation of a strong bullish trend, carried forward from the last two days. This upscale in growth magnitude comes after a successful month of staggering growth for the stock nearing 53%. Just last week, the WEAT story was widely shared across various platforms reaching a 53-week high in share price. Market bulls describe WEAT as having high financial value, given broader developments across the globe. Tensions in Europe appear to be the fundamental driver in this phenomenal swing. Furthermore, its growth, which has been three times that of crude oil is sending the market towards a ‘rush’.

    Global Wheat Supply Disruptions & Inflationary Pressures

    These gains in WEAT prices are linked to disruptions brought about in the global wheat supply amidst the Russia-Ukraine conflict. Both countries account for a combined 29% of the global wheat supply, triggering a shoot up of wheat futures prices. As Russia continues to capture strategic port cities across Ukraine, the export of this crucial commodity continues to face threats. With Ukraine close to logistical incapacitation, and Russia severely sanctioned, the future of wheat supply looks bleak, creating a market-wide frenzy.

    Wheat futures prices were soaring at record highs well before the armed conflict in Eastern Europe. Global inflationary pressures following coronavirus-related economic disruptions further swelled wheat prices. Just within a year, prices saw a hike of 40%, creating panic among consumers, and creating demand for wheat futures. Alternatively, bulls in the market see opportunity within the crisis, as a means to gain exposure to these price climbs.

    Opportunities for Traders seeking Exposure to WEAT Futures Growth

    Moreover, with European stocks continuing their downward spiral, investors are increasingly looking towards strategic diversification of their portfolios. Commodities, unlike other financial securities, tend to show relatively less risky behavior in times of crisis. The agricultural industry, in particular, is a lucrative option, given the volatilities seen in the oil and gas sectors.

    Each of these broader concerns highlights why the market is seemingly rushing to get its hands on wheat futures. Teucrium Wheat, an ETF dealing specifically in wheat futures offers this exposure and security to market participants. As uncertainty regarding the future supply of global wheat continues to become a concern, the purchase of wheat futures continues. The significant volume of trade seen in the previous hours is a strong indicator of this.

  • Briefing from Pluretism (PSTI) CEO gets Hopes Up. Stock Balloons in the Pre-market

    Briefing from Pluretism (PSTI) CEO gets Hopes Up. Stock Balloons in the Pre-market

    Pluristem Therapeutics Inc. (NASDAQ: PSTI) has continued its impressive bullish trajectory for the last 14 days. Although growth on Thursday was a modest 2.75%, it was during pre-market that traders were truly taken aback. The stock ballooned up by a whopping 4.28%. Retail traders, as well as longer-term investors, continue to monitor movement, with ears open to any news surrounding Pluristem Therapeutics.

    Updates on PSTI Ambitions for the Year

    Potential investors are keenly eyeing the prospects of Pluristem Therapeutics. Making the rounds amongst wider discourse this week, The Israeli developer of cell-therapy-based products has big ambitions for this year.  Recent developments that have been emerging have primarily caused the recent hysteria around PSTI, leading to heightened chatter. The hype surrounding PSTI stock can be traced back to Tuesday when CEO Yaky Yanay briefed shareholders on crucial updates. These had included the following breakthroughs:

    • Partnership with Israeli food-producing giant, Tnuva for the development of cultured meat solutions. With Pluristem’s vast experience and expertise around stem cell development, there is clear potential for global leadership within this domain. This emerging industry holds immense growth potential for PSTI.
    • The company has a strong pipeline of innovative and revolutionary candidates for stem-cell treatment approaching actualization this year. This includes a phase III trial on muscle regeneration, along with a phase I trial relating to hematopoietic cell transplantation. The company is further optimistic about next-gen biomedical solutions, such as induction and CRISPR. Each constituent initiative within the company’s impressive portfolio of projects could result in breakthroughs that could redefine the biopharmaceutical realm. Pluristem could likely become a world leader in these cutting-edge domains, shortly.
    • An initiative to expand commercial capabilities in the coming years to diversify the application of the company’s stem cell products. The company plans on expanding its collaboration with different industries to work towards this strategic vision. The hiring of Chief Commercial Officer, Nimrod Bar Zvi, further reinforces this strategic goal.

    Conclusion

    Each of these critical updates emphasizes the growth potential that PSTI is yet to realize. The trade figures about the PSTI stock had gone on to reflect this sudden optimism. Investors are eagerly watching the magnitude of this growth trend, which is evident by its sheer trade volume.

  • Milestone Update brings Significant Gains to Statera Biopharma Inc (STAB)

    Milestone Update brings Significant Gains to Statera Biopharma Inc (STAB)

    From within the penny stocks realm, Statera Biopharma, Inc. (NASDAQ: STAB) has had remarkable performance late yesterday. The stock which has been increasingly gaining attention saw significant climbs of up to 36.99% later into the after-hours of trade. A sharp spike in share price had followed after a steady incline of 6.85% immediately upon the closure of trading. These shifts in STAB stock price come about after four months of a persistent downward slide.

    STAB’s Submission of Phase 1 Trials to FDA

    The developments come after the leading biopharmaceutical company announced the submission of phase 1 clinical trials of the STAT-205 development. The submission acts as a major milestone in the lifecycle of treatment development, pushing the outcome closer to actualization. Long-term post-Covid conditions, such as inflammation, would be adequately addressed, given the design specifics of the drug. Pathogenicity would adequately be addressed as a result of the Statera Biopharma treatment, through balancing immune system function, and by employing immunomodulators.

    As the world edges on closer towards a post-Covid reality, treatments such as Statera Biopharma’s STAT-205 become ever more crucial. The nature of such products in the pharmaceutical industry ensures a smooth transition in the medical world. Given the potential value addition, such a product would offer, it is clear why the market is betting on its success.

    Phase 3 Approval of STAB drug by FDA

    Confidence in Statera Biopharma sees further reinforcement, given earlier developments the company had announced. Last month, investors welcomed news of the company’s STAT-201 gaining approval by the FDA-mandated, Central Institutional Review Board. The phase 3 trial drug, which is a next-gen treatment for Crohn’s disease, acts as an immune-modulator. A track record such as this further strengthens Statera Biopharma’s credentials, instilling confidence amongst market participants of the company’s initiatives.

    This string of positive announcements comes when a general downward market trend for STAB sees a much-needed reversal. This is not the first time the STAB stock trajectory has seen potentially monumental gains in a broader bearish trajectory. The stock has lost near 67% of its value from a year ago, followed by an 83% spike. This indicates the nature of biopharmaceutical stock, which is critically dependent upon positive updates regarding prospects.

    Conclusion

    The STAB stock is currently experiencing a significant climb in the after-hours, following significant milestone updates regarding its initiatives. With investors seeing optimism regarding the potential launch of crucial treatments, there has been an emphasis on the credentials of Statera Biopharma.

  • NCNA sees Hard Plummet following Announcement of Clinical Trial Discontinuation

    NCNA sees Hard Plummet following Announcement of Clinical Trial Discontinuation

    Following the week-long bullish trend in the case of NuCana PLC (NCNA), the stock is undergoing a significant reversal.  Following the close of yesterday’s trading session, the stock value plummeted by 55.10%, to the dismay of those taking long positions in the current market session. This sudden swing comes directly as a result of newly released information making the rounds across the market.

    NCNA Hopes Shattered with Discontinuation Announcement

    The British biotech, Nucana PLC announced earlier today its decision to discontinue phase 3 trials of Acelarin. The treatment agent for biliary tract cancer was currently undergoing development procedures. A number of investors were betting on this drug’s approval leading to the value breakthrough they were widely anticipating. It did not take long for NCNA stock to plummet shortly after this announcement, as traders swiftly began losing confidence.

    The FDA had approved a fast-tracking of the clinical development, a move that raised the hopes of potential investors. Ever since September last year, Nucana PLC has been eagerly putting forward its ambitions with the promising drug. The company’s data monitoring committee pointed to feasibility flaws, deeming it unlikely to meet core project objectives. In response, the company’s founder and CEO,  Hugh Griffith expressed serious disappointment to the circumstances faced. He had attributed the development to “the challenges associated with developing new medicines for patients with biliary tract cancer”. The management, however, remains hopeful with regards to two of its other clinical trials addressing treatments for colorectal cancer, as well as lymphoma tumors. The discontinuation of Acelarin does come as a low blow for Nucana, however, the progress of the remaining projects remains critical.

    Unprecedented Value Plummet for NCNA

    Currently, NCNA is valued at the lowest its been throughout its trading history, which signifies the magnitude of the recent news. This hard plummet had come after a general bullish trend in continuation from August of 2018. This swing had gone on to wipe out over 73% of Nucana’s market capitalization. As of yet, the stock is making a steady rise of 13% following the beginning of the regular trade session. The magnitude of this recovery remains unclear to traders as of yet.

    Conclusion

    The NCNA stock went through a hard plummet, following news of a discontinued clinical trial by the management. This is the worst-hit the stock has taken since its trade history, and traders are uncertain as to the recovery of the stock’s value.